Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 48.6%

Neg 0% Neu 48.6% Pos 0%

Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $11 price target.